Skip to main content

Official Journal of the Italian Society of Orthopaedics and Traumatology

Table 4 Dosage and time of administration of available new oral anticoagulants (NOA)

From: Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery

Active principle

Brand name

Dosage and time of administration

Dabigatrana

(antifactor IIa)

Pradaxa®

110 mg 1–4 h after surgery, then 220 mg/day

If age > 75 years or creatinine clearance 30–50 ml/min or amiodarone intake, 75 mg 1–4 h after surgery, then 150 mg/day

Rivaroxabanb

(antifactor Xa)

Xarelto®

10 mg 6–10 h after surgery, then 10 mg/day

  1. aDabigatran has proved not to be inferior to low-molecular-weight heparin (LMWH) both in terms of efficacy and safety. As concerns dabigatran, in the literature, there is no information available on patients undergoing regional anaesthesia [11, 12]
  2. bRivaroxaban has shown to have greater efficacy than LMWH, with overlapping safety [13–16]. An analysis performed after publication of rivaroxaban registration study confirmed its safety in patients undergoing neuraxial anesthesia